Market Research Report
Asia Pacific Diabetes Drugs Maret Forecast 2019-2027
|Published by||Inkwood Research||Product code||618293|
|Published||Content info||76 Pages
Delivery time: 1-2 business days
|Asia Pacific Diabetes Drugs Maret Forecast 2019-2027|
|Published: October 8, 2018||Content info: 76 Pages||
The CAGR for the Asia Pacific diabetes drugs market is expected to be 10.82% for the forecast period of 2019-2027. Economic development and rise in healthcare spending are expected to increase the demand for diabetes drugs further. Despite a large number of people with diabetes in the region, awareness is still low, and therefore the situation needs to be addressed.
Diabetes is associated with a myriad of complications which affect the feet, eyes, kidneys, and cardiovascular health. Nearly half of people with diabetes remain undetected, accounting for complications at the time of diagnosis. Screening can differentiate an asymptomatic individual at high risk from one at low risk for diabetes. Another reason attributed to the increase in the prevalence of diabetes can possibly be the increase in dietary fat and protein consumption, as well as the expanding elderly population.
Prominent players in the Asia Pacific diabetes drugs market are Eli Lilly And Company, Astellas Pharma, B.Braun Melsungen Ag, Novo Nordisk A/S, Diavacs Inc., Sanofi, Astrazeneca Plc., Albireo Pharma Inc. Macrogenics, Inc., Xoma Corp., Glaxosmithkline, Xeris Pharmaceuticals, Merck and Pfizer.